Drug Interaction Report
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- ripretinib
- trofinetide
Drug interactions
Moderate drug interactions
Moderate:ripretinib trofinetide
Applies to: ripretinib, trofinetide
Trofinetide may increase the blood levels of ripretinib in some patients. This may increase the risk and/or severity of side effects such as:
- nausea
- vomiting
- constipation
- diarrhea
- hair loss
- muscle pain
- high blood pressure
- heart failure
- skin reactions
- skin cancers
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.
Let your doctor know if you develop redness, pain, blisters, rash, bleeding, or swelling on the palms of your hands or soles of your feet, as these may be signs and symptoms of a potentially severe and painful condition known as Palmar-Plantar Erythrodysesthesia Syndrome (PPES), or hand-foot syndrome.
Also seek medical attention if you experience signs and symptoms of heart failure such as:
- fatigue
- shortness of breath
- protruding neck veins
- water retention
- swelling in the abdomen, legs or ankles
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:Food/Lifestyle ripretinib
Applies to: ripretinib
Grapefruit juice may increase the blood levels of certain medications such as ripretinib.
You may want to limit your consumption of grapefruit and grapefruit juice during treatment with ripretinib. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication.
Contact your doctor if your condition changes or you experience increased side effects.
Orange juice is not expected to interact.
Disease interactions
5 potential interactionsApplies to: 5 conditions, including High Blood Pressure, Heart Disease, Bleeding Disorder, Cardiovascular Conditions and Disorders, and Coagulation Defects and Disorders.
Bleeding Disorder
Moderate:ripretinib
Ripretinib has a moderate potential interaction with Bleeding Disorder.
Ripretinib has the potential to affect wound healing adversely. Do not administer ripretinib for at least two weeks following major surgery and until adequate wound healing. It is recommended to withhold ripretinib for at least one week before elective surgery. Care should be exercised when using this agent in patients with impaired wound complications. The safety of this agent after the resolution of wound healing complications has not been established.
Cardiovascular Conditions and Disorders
Moderate:ripretinib
Ripretinib has a moderate potential interaction with Cardiovascular Conditions and Disorders.
Ripretinib may cause cardiac dysfunction. The safety of ripretinib has not been assessed in patients with a baseline ejection fraction below 50%. Assess ejection fraction by echocardiogram or multiple gated acquisition (MUGA) scan prior to initiating treatment with ripretinib and during treatment, as clinically indicated. Permanently discontinue therapy for Grade 3 or 4 left ventricular systolic dysfunction.
Coagulation Defects and Disorders
Moderate:ripretinib
Ripretinib has a moderate potential interaction with Coagulation Defects and Disorders.
Ripretinib has the potential to affect wound healing adversely. Do not administer ripretinib for at least two weeks following major surgery and until adequate wound healing. It is recommended to withhold ripretinib for at least one week before elective surgery. Care should be exercised when using this agent in patients with impaired wound complications. The safety of this agent after the resolution of wound healing complications has not been established.
Heart Disease
Moderate:ripretinib
Ripretinib has a moderate potential interaction with Heart Disease.
Ripretinib may cause cardiac dysfunction. The safety of ripretinib has not been assessed in patients with a baseline ejection fraction below 50%. Assess ejection fraction by echocardiogram or multiple gated acquisition (MUGA) scan prior to initiating treatment with ripretinib and during treatment, as clinically indicated. Permanently discontinue therapy for Grade 3 or 4 left ventricular systolic dysfunction.
High Blood Pressure
Moderate:ripretinib
Ripretinib has a moderate potential interaction with High Blood Pressure.
Ripretinib may cause hypertension. It is recommended to control blood pressure prior to initiating therapy and monitor blood pressure as clinically indicated during treatment. Based on severity, withhold treatment with ripretinib and resume at the same or reduced dose or permanently discontinue. Do not initiate ripretinib in patients with uncontrolled hypertension.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.